Navigation Links
MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study

WARREN, N.J., Feb. 21 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has successfully completed a pilot clinical study for its thin film formulation of ondansetron, a selective 5-HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting.

MonoSol Rx's thin film formulation of ondansetron was studied against GlaxoSmithKline's Zofran ODT(R) product. Based on the results of the study, MonoSol Rx is moving immediately to pivotal trials to enable drug submissions both in the US and Europe. The Company expects to file with the appropriate regulatory authorities in 2008.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Successful completion of this pilot study marks an important step towards commercializing what we believe is a product with significant benefits over existing formulations of ondansetron. Our thin film formulation of ondansetron is particularly well suited for the target patient population because individuals who are prescribed the drug often have difficulty swallowing due to extreme nausea caused by chemotherapy, radiotherapy and surgical procedures. Incorporating ondansetron into a great-tasting thin film formulation that dissolves quickly in the mouth allows the drug to be easily administered without water, making it more palatable and less likely to cause additional discomfort."

MonoSol Rx's formulation of ondansetron is a new oral formulation expected to be introduced to the market next year. Its indications are the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV), prevention of nausea and vomiting associated with radiotherapy, and prevention of Post-Operative Nausea and Vomiting (PONV).

MonoSol Rx's thin film technology utilizes strategic and proprietary intellectual property that ensures predictable in-vivo performance and provides superior characteristics over other delivery forms including competing film products. MonoSol Rx's intellectual property includes thin film producing polymers, drug taste masking, processes that ensure product and content uniformity at scale, novel packaging and in-process testing methods.

Mr. Schobel continued, "The strength of our pipeline and intellectually property, combined with the convenience and potential dosing benefits of our thin film technology, sets MonoSol Rx apart as an innovator in the drug delivery sector. As the pharmaceutical industry evolves and more blockbuster drugs transition to generic, MonoSol Rx's objective is to leverage our thin film technology via partnerships and self-funded development initiatives to bring new products to market that enhance the effectiveness and market-appeal of already-approved compounds. We believe this strategy will enable MonoSol Rx to cement its leadership position in the thin film drug delivery market."

MonoSol Rx has signed a term sheet and is in final negotiations with a partner to market its thin film formulations for ondansetron in 4 and 8 mg strengths. Negotiations are expected to conclude prior to global regulatory submissions.

Keith Kendall, chief financial officer for MonoSol Rx, commented, "Completing an agreement with a partner for our ondansetron formulation should further solidify the market potential of MonoSol Rx's technology and continue to demonstrate our ability to develop and manufacture prescription thin film products at scale for our partners. This agreement would build upon the development and supply agreement that we signed with Adams Respiratory Therapeutics in March 2007 for another, as-yet-unnamed prescription product."

With an annual prescription market of $1.2 billion in the US and approx $100 million in the top-five European countries, ondansetron is recognized as the leading 5-HT3 antagonist used in the prevention and treatment of nausea and vomiting.

About MonoSol Rx

MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company's thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprietary encapsulation compositions to mask the taste of the drug contained within the film. The Company's thin film formulations offer significant patient benefits, including convenience, taste, and potentially greater efficacy. MonoSol Rx's strategy is to develop and partner innovative thin film strip products in the prescription, generic and OTC pharmaceutical markets and to establish a leadership position in thin film drug delivery technology through continued development of its drug delivery technology and intellectual property portfolio.

Media / Investors: Contact:

The Ruth Group MonoSol Rx

Jason Rando / Elizabeth Scott Keith Kendall

(646) 536-7025 / 7014 Chief Financial Officer (732) 564-5000

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):